Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans.

@article{Otsuka2014PathologyOS,
  title={Pathology of second-generation everolimus-eluting stents versus first-generation sirolimus- and paclitaxel-eluting stents in humans.},
  author={Fumiyuki Otsuka and Marc Vorpahl and Masataka Nakano and Jason R. Foerst and John Newell and Kenichi Sakakura and Robert Kutys and Elena R Ladich and Aloke Virmani Finn and Frank D Kolodgie and Renu Virmani},
  journal={Circulation},
  year={2014},
  volume={129 2},
  pages={211-23}
}
BACKGROUND Clinical trials have demonstrated that the second-generation cobalt-chromium everolimus-eluting stent (CoCr-EES) is superior to the first-generation paclitaxel-eluting stent (PES) and is noninferior or superior to the sirolimus-eluting stent (SES) in terms of safety and efficacy. It remains unclear whether vascular responses to CoCr-EES are different from those to SES and PES because the pathology of CoCr-EES has not been described in humans. METHODS AND RESULTS A total of 204… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 5 times over the past 90 days. VIEW TWEETS
112 Citations
31 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 112 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Similar Papers

Loading similar papers…